Advertisement

Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis

  • Razi Khan
  • Eric Rheaume
  • Jean-Claude Tardif
Evidence-Based Medicine (L. Roever, Section Editor)
  • 182 Downloads
Part of the following topical collections:
  1. Topical Collection on Evidence Based Medicine

Abstract

Purpose

The purpose of this review was to examine the role of IL-1β in the inflammatory process central to the development of atherosclerosis and to discuss current clinical evidence for treatments targeting IL-1β in coronary artery disease.

Recent Findings

IL-1β has been shown to modulate atherosclerotic plaque progression by upregulating the synthesis of adhesion molecules on endothelial cells, as well increasing activation and proliferation of vascular smooth muscle cells. Animal studies have further suggested that alterations in the balance between agonists and antagonists of IL-1β are important in promoting atherosclerosis. In humans, preliminary assessment of therapy targeting IL-1β noted early reductions in serum inflammatory biomarkers among those with systemic inflammatory or coronary artery disease. The CANTOS trial, a large randomized double-blind study found that canakinumab, a monoclonal antibody targeting IL-1β, reduced ischemic events in patients being treated for secondary prevention.

Summary

Cellular, animal, and now clinical studies have suggested a role for therapies aimed at IL-1β for treatment of CAD. However, given potential side effects and costs of these medications, further study is required to determine which patients may be most suited for treatment above current standard of care.

Keywords

Interleukin-1β Atherosclerosis Coronary artery disease Inflammation 

Notes

Compliance with Ethical Standards

Conflict of Interest

Razi Khan, Eric Rheaume, and Jean-Claude Tardif declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. 1.
    Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. American Heart Association statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322.PubMedGoogle Scholar
  2. 2.
    Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.CrossRefGoogle Scholar
  3. 3.
    Isoda K, Ohsuzu F. The effect of interleukin-1 receptor antagonist on arteries and cholesterol metabolism. J Atheroscler Thromb. 2006;13:21–30.CrossRefGoogle Scholar
  4. 4.
    • Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–50 Comprehensive review examining the role of IL-1 family in mediating inflammation. CrossRefGoogle Scholar
  5. 5.
    •• Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA Jr. Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion. Am J Pathol. 1985;121:394 Major study describing in vivo effects of IL-1β on vascular endothelial cells. PubMedPubMedCentralGoogle Scholar
  6. 6.
    Tamaru M, Tomura K, Sakamoto S, Tezuka K, Tamatani T, Narumi S. Interleukin-1beta induces tissue- and cell type-specific expression of adhesion molecules in vivo. Arterioscler Thromb Vasc Biol. 1998;18:1292–303.CrossRefGoogle Scholar
  7. 7.
    • Varghese GP, Folkersen L, Strawbridge RJ, Halvorsen B, Yndestad A, Ranheim T, et al. NLRP3 inflammasome expression and activation in human atherosclerosis. J Am Heart Assoc. 2016;5:e003031 Study comparing expression of inflammasome in atherosclerotic arteries and non-diseased arteries. Google Scholar
  8. 8.
    Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13:323–40.CrossRefGoogle Scholar
  9. 9.
    Clarke MCH, Talib S, Figg NL, Bennett MR. Vascular smooth muscle cell apoptosis induces interleukin-1–directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res. 2010;106:363–72.CrossRefGoogle Scholar
  10. 10.
    Clément N, Gueguen M, Glorian M, Blaise R, Andréani M, Brou C, et al. Notch3 and IL-1β exert opposing effects on a vascular smooth muscle cell inflammatory pathway in which NF-κB drives crosstalk. J Cell Sci. 2007;120:3352–61.CrossRefGoogle Scholar
  11. 11.
    Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest. 1990;85:731–8.CrossRefGoogle Scholar
  12. 12.
    • Chamberlain J, Gunn J, Francis S, Holt C, Crossman D. Temporal and spatial distribution of interleukin-1β in balloon injured porcine coronary arteries. Cardiovasc Res. 1999;44:156–65 Study looking at IL-1β synthesis in porcine coronary arteries in response to arterial inflammation. CrossRefGoogle Scholar
  13. 13.
    Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M, et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest. 1996;97:769–76.CrossRefGoogle Scholar
  14. 14.
    Isoda K, Shiigai M, Ishigami N, Matsuki T, Horai R, Nishikawa K, et al. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation. 2003;108:516–8.CrossRefGoogle Scholar
  15. 15.
    Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res. 2005;66:583–93.CrossRefGoogle Scholar
  16. 16.
    Nicklin MJH, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med. 2000;191:303–12.CrossRefGoogle Scholar
  17. 17.
    Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M, et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2004;24:1068–73.CrossRefGoogle Scholar
  18. 18.
    Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, et al. Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:656–60.CrossRefGoogle Scholar
  19. 19.
    Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E–deficient mice. Circulation. 1998;97:242–4.CrossRefGoogle Scholar
  20. 20.
    Devlin CM, Kuriakose G, Hirsch E, Tabas I. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci. 2002;99:6280–5.CrossRefGoogle Scholar
  21. 21.
    Morton AC, Arnold ND, Gunn J, Varcoe R, Francis SE, Dower SK, et al. Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model. Cardiovasc Res. 2005;68:493–501.CrossRefGoogle Scholar
  22. 22.
    Chi H, Messas E, Levine RA, Graves DT, Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation. 2004;110:1678–85.CrossRefGoogle Scholar
  23. 23.
    Bhaskar V, Yin J, Mirza AM, Phan D, Vanegas S, Issafras H, et al. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in apolipoprotein E-deficient mice. Atherosclerosis. 2011;216:313–20.CrossRefGoogle Scholar
  24. 24.
    • Roubille F, Busseuil D, Shi Y, Nachar W, Mihalache-Avram T, Mecteau M, et al. The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis. 2014;236:277–85 Study where use of monoclonal antibody targeting IL-1β mitigated neointimal thickening in response to arterial inflammation. CrossRefGoogle Scholar
  25. 25.
    • Granowitz EV, Poutsiaka DD, Cannon JG, Wolff SM, Dinarello CA, Santos AA, et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet. 1991;338:1423–4 Study that proposes use of IL-1Ra as serum biomarker for inflammation rather than IL-1β. CrossRefGoogle Scholar
  26. 26.
    Patti G, D'Ambrosio A, Dobrina A, Dicuonzo G, Giansante C, Fiotti N, et al. Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease. J Thromb Thrombolysis. 2002;14:139–43.CrossRefGoogle Scholar
  27. 27.
    Patti G, D'Ambrosio A, Mega S, Giorgi G, Zardi EM, Zardi DM, et al. Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J Am Coll Cardiol. 2004;43:35–8.CrossRefGoogle Scholar
  28. 28.
    Patti G, Mega S, Pasceri V, Nusca A, Giorgi G, Zardi EM, et al. Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction. Clin Cardiol. 2005;28:193–6.CrossRefGoogle Scholar
  29. 29.
    Patti G, Di Sciascio G, D’Ambrosio A, Dicuonzo G, Abbate A, Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2002;89:372–6.CrossRefGoogle Scholar
  30. 30•.
    . Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99:2079–84 Study examining prognostic impact of changes in serum IL-1Ra levels in patients admitted with unstable angina. CrossRefGoogle Scholar
  31. 31••.
    . Schofer N, Ludwig S, Rübsamen N, Schnabel R, Lackner KJ, Ruprecht HJ, et al. Prognostic impact of Interleukin-1 receptor antagonist in patients with documented coronary artery disease. Int J Cardiol. 2018;257:24–9 Large observational study examining prognostic impact of serum IL-1Ra levels in patients with ACS and stable angina. CrossRefGoogle Scholar
  32. 32•.
    . Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation. 1999;99:861–6 Observational study that noted association between IL-1Ra and single-vessel CAD. CrossRefGoogle Scholar
  33. 33.
    Kastrati A, Koch W, Berger PB, Mehilli J, Stephenson K, Neumann F-J, et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol. 2000;36:2168–73.CrossRefGoogle Scholar
  34. 34.
    Francis SE, Camp NJ, Burton AJ, Dewberry RM, Gunn J, Stephens-Lloyd A, et al. Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty. Heart. 2001;86:336–40.CrossRefGoogle Scholar
  35. 35.
    Hoppmann P, Koch W, Laugwitz K-L, Kastrati A. Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents. Coron Artery Dis. 2014;25:658–64.CrossRefGoogle Scholar
  36. 36.
    • Zhou L, Cai J, Liu G, Wei Y, Tang H. Associations between interleukin-1 gene polymorphisms and coronary heart disease risk: a meta-analysis. PLoS one. 2012;7:e45641 Meta-analysis suggesting no relationship between IL-1Ra gene polymorphism and CAD. CrossRefGoogle Scholar
  37. 37.
    • Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation. 2013;128:1910–23 Review detailing pharmacodynamics of IL-1β inhibitors. CrossRefGoogle Scholar
  38. 38.
    Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, et al. Inhibition of interleukin-1 by Anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117:2662–9.CrossRefGoogle Scholar
  39. 39.
    Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GGL, Van Tassell BW, Robati R, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010;105:1371–1377. e1.CrossRefGoogle Scholar
  40. 40.
    Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra remodeling trial (2)(VCU-ART2) pilot study]. Am J Cardiol. 2013;111:1394–400.CrossRefGoogle Scholar
  41. 41.
    Abbate A, Kontos MC, Abouzaki NA, Melchior RD, Thomas C, Van Tassell BW, et al. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol. 2015;115:288–92.CrossRefGoogle Scholar
  42. 42.
    • Morton AC, Rothman AMK, Greenwood JP, Gunn J, Chase A, Clarke B, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2014;36:377–84 Trial examining the effect of IL-1β inhibition on inflammatory biomarkers in patients with recent MI. CrossRefGoogle Scholar
  43. 43.
    Choudhury RP, Birks JS, Mani V, Biasiolli L, Robson MD, L'Allier PL, et al. Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance. J Am Coll Cardiol. 2016;68:1769–80.CrossRefGoogle Scholar
  44. 44.
    •• Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. New Engl J Med. 2017;377:1119–31 Landmark clinical trial examining IL-1β blockade in patients. CrossRefGoogle Scholar
  45. 45•.
    . Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1833–42 CANTOS substudy looking at IL-1β inhibition and lung cancer incidence and mortality. CrossRefGoogle Scholar
  46. 46•.
    . Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol. 2018;71:2392–401 CANTOS substudy looking at IL-1β inhibition in diabetics. CrossRefGoogle Scholar
  47. 47•.
    . Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391:319–28 CANTOS substudy examining response of inflammatory markers to IL-1β inhibition therapy. CrossRefGoogle Scholar
  48. 48.
    Khan R, Spagnoli V, Tardif J-C, L'Allier PL. Novel anti-inflammatory therapies for the treatment of atherosclerosis. Atherosclerosis. 2015;240:497–509.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Royal Columbian HospitalNew WestminsterCanada
  2. 2.Montreal Heart InstituteMontrealCanada

Personalised recommendations